Protease nexin 1 (PN1) is a serine protease inhibitor (SERPIN) that acts as a suicide substrate for thrombin (Th) and urokinase-type plasminogen activator (uPA). PN1 forms 1:1 stoichiometric complexes with these proteases, which are then rapidly bound, internalized, and degraded. The low density lipoprotein receptor-related protein (LRP) is the receptor responsible for the internalization of protease-PN1 complexes. However, we found that the LRP is not significantly involved in the initial cell surface binding of thrombin-PN1, leading us to investigate what cellular component was responsible for this initial interaction. Since Th-PN1 complexes retain a high-affinity for heparin after complex formation, unlike several of the other SERPINs, we tested the possibility that cell surface heparins were involved in initial complex binding. Soluble heparin was found to be a potent inhibitor of the binding of Th-PN1 to the cell surface and greatly facilitated the dissociation of Th-PN1 complexes pre-bound in the absence of soluble heparin. To ascertain the role of cell surface heparins, further studies were done using complexes of thrombin and PN1(K7E), a variant of PN1 in which the heparin binding site was rendered non-functional. When added at equal initial concentrations of complexes, Th-PN1(K7E) was catabolized 5-to 10-fold less efficiently than Th-PN1, a direct result of the greatly diminished initial binding of the Th-PN1(K7E) complexes. These data demonstrate the sizable contribution of cell surface heparins to Thrombin-PN1 complex binding and support a model in which these heparins act to concentrate the complexes at the cell surface facilitating their subsequent LRP-dependent endocytosis.
Protease nexin 1 (PN1)
1 is a 43-kDa serine protease inhibitor that is a member of the SERPIN superfamily (1) . It is an important physiological regulator of thrombin in tissues, and like its plasma counter part, antithrombin III, it is activated by heparin (1, 2) . Like other members of the SERPIN family, PN1 is proteolytically attacked by its target protease but arrests proteolytic cleavage resulting in the formation of a 1:1 stoichiometric complex with that protease (1, 2) . Only PN1 that is in complex with a protease is internalized and degraded by cells at a significant rate (3) . This is presumably due to the formation or unmasking of a receptor binding site in PN1 when in complex with a protease, which is absent in the free SERPIN. One candidate site within the PN1 sequence for this function has recently been identified (4) . Mechanistically, this ensures that SERPINs will remain extracellular until they have become part of an inhibitory complex. Once they have formed an inhibitory complex with a protease, the rapid removal of protease-SERPIN complexes is important for two reasons. First, since there is evidence to suggest that protease-SERPIN complexes may not be covalently linked (5) , the uninternalized complexes represent a potential source of active protease formed when the complexes dissociate. Second, in the case of one SERPIN, ␣1-antitrypsin (␣1-AT), the internalization of protease-␣1-AT complexes generates an intracellular signal that leads to an up-regulation of ␣1-AT synthesis and secretion (6) . The expression of another SERPIN, tissue-type plasminogen activator, is down-regulated when it forms complexes with the protease, plasminogen activator inhibitor type 1, that are internalized (7) .
The molecule responsible for the endocytosis of complexed PN1 (either with thrombin (Th) or urokinase-type plasminogen activator (uPA)) has been identified as the low density lipoprotein receptor-related protein (LRP) (8) . Interestingly, although the LRP is required for the internalization of both types of complexes, it does not act as the primary receptor responsible for the concentration of complexes to the cell surface. In the case of uPA-PN1 complexes, the urinary plasminogen activator receptor (uPAR) acts as the primary receptor. The uPA-PN1 complexes and the uPAR are then co-endocytosed by an LRPdependent mechanism (9) . Importantly, however, the uPAR does not act as the primary receptor for PN1 in complex with its other target protease, thrombin (Th-PN1 complexes). This was demonstrated by showing that Th-PN1 complexes did not compete for the binding of uPA-PN1 complexes to the uPAR (8) . Thus, in the case of protease-PN1 complexes, the protease moiety of the inhibitory complex can determine the initial binding interaction at the cell surface.
Several recent studies have demonstrated the involvement of the LRP in the endocytosis of Th-PN1 complexes (8, 10) , including the recent identification of a site in PN1 that binds to the LRP (4) . The present studies were prompted by our observation that the binding of Th-PN1 complexes to the cell surface is not competed for significantly by the receptor associated protein (RAP), which inhibits the binding of all known ligands to the * This work was supported by NIH Grant RO1-GM34001-09. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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LRP, and that Th-PN1 complexes do not bind to the uPAR (8) .
Since it has been previously demonstrated that the binding of Th-PN1 complexes is inhibited by soluble heparin (3), we tested the possibility that heparin sulfate may be involved in the cell surface binding of Th-PN1 complexes prior to LRP-mediated internalization. In the present studies, we demonstrate that soluble heparin is a very potent competitor for the binding of Th-PN1 complexes to the surface of human foreskin fibroblasts (HF) and mouse embryo fibroblasts (MEF). In addition, a recombinant form of PN1, in which the heparin binding site has been rendered non-functional, is internalized and degraded at 10 -20% of the efficiency of recombinant native PN1 by MEF. In a paired mouse embryo cell strain that is LRP-deficient (PEA-13 cells), catabolism of the heparin binding deficient form of PN1 is barely detectable. Taken together, these data support a model in which the Th-PN1 complexes are first concentrated to the cell surface by heparins and subsequently internalized by the LRP.
EXPERIMENTAL PROCEDURES
Materials-Tissue culture dishes and plasticware were purchased from Corning, Inc., and medium was purchased from Irvine Scientific. BaculoGold baculovirus and High Five insect cells were purchased from PharMingen. Oligonucleotides were purchased from IDT Technologies, and Taq polymerase was from Invitrogen. 1,3,4,6-Tetrachloro-3␣-3␣-diphenylglycouril (Iodogen) was from Pierce.
125 I-Na was obtained from Amersham Corp. electrophoresis reagents were from Bio-Rad, X-OMAT AR x-ray film was from Kodak, and Immobilon-P membrane was from Millipore. All other common reagents were from Sigma.
Cell Culture-Stocks of primary cultures of human foreskin fibroblasts were grown as described (11) . Confluent cell cultures were serum starved for 24 -72 h in binding media (Dulbecco's modified Eagle's medium without serum, containing 1 mg/ml bovine serum albumin (BSA) and 20 mM Hepes buffer, pH 7.2) prior to use in experiments. Normal MEF and PEA-13 cells (MEF deficient in the LRP) were a generous gift from Dr. Joachim Herz (12) . These cells were grown in the same medium and subcultured as described for human fibroblasts (11) .
RAP-GST Expression and Purification-The RAP protein was expressed as a fusion protein (RAP-GST) consisting of an amino-terminal glutathione S-transferase sequence followed by the rat RAP sequence. The fusion protein was affinity purified on a glutathione-Sepharose column as described (13) .
Generation of the K7E Variant of Human PN1-Overlapping PCR was used to generate a variant form of PN1 in which the seven lysine residues in the heparin binding site were changed to glutamic acid as described previously (14) . These included lysine residues 71, 74, 75, 78, 83, 84, and 86. All of the changes were verified by sequence analysis (data not shown). The variant form of PN1 was co-transfected into Sf9 insect cells with BaculoGold baculovirus, and the recombinant virus was recovered by plaque purification as described previously (15) . The recombinant viruses were used to infect Sf9 insect cells for protein production as described previously (15) . Both PN1 and PN1(K7E) were purified using Cibacron blue-Sepharose as described previously (14) .
Radioiodinations-Thrombin was radioiodinated using Iodogen as described previously (16) . Specific activities ranged from 15,000 to 22,000 cpm/ng. Fluoresceinated heparin (F-heparin) was radioiodinated using Iodogen as described previously (17) . Specific activities ranged from 40,000 to 70,000 cpm/ng. I-Th-PN1 complexes and 125 I-Th-PN1(K7E) complexes was performed as described (3) . Recombinant PN1(K7E) expressed by a baculovirus expression vector was purified from medium harvested from insect cells as described previously (15) . After purification, PN1 and PN1(K7E) were active site titrated with thrombin using a chromogenic substrate assay as described previously (11) .
125
I-Thrombin-PN1 Complex Degradation-Confluent cell cultures in 24-well dishes were rinsed in bicarbonate-free Dulbecco's modified Eagle's medium containing 1 mg/ml BSA and 20 mM Hepes buffer, pH 7.2. One ml of this binding medium, containing 125 I-Th-PN1 complexes at the indicated concentrations, was added to each well and the cultures were incubated at 37°C. At the indicated times, 100 l of the media from individual wells were added to microfuge tubes containing 1.0 ml of 12% ice-cold trichloroacetic acid (TCA). After a 1-h incubation on ice, precipitates were pelleted by centrifugation, and the supernatants were counted in a ␥ counter. Background degradation determined from complexes incubated in medium in the absence of cells was subtracted at each timepoint.
Cell Surface Binding of Complexes at 4°C or Cell Association of Complexes at 37°C-Fibroblast cell cultures were incubated with binding media containing 125 I-Th-PN1 complexes and competing ligands as described above. At the end of the incubations, unbound complexes were removed by aspiration. The cells were washed 4 times with ice-cold phosphate-buffered saline (PBS) and lysed with 10% SDS, and the cell lysates were counted in a ␥ counter. Nonspecific binding, approximately 30% of total binding, was determined by incubating 3 wells at each temperature with a 400-fold excess of unlabeled complexes.
125 I-Heparin Binding to PN1 and PN1(K7E)-Two g of PN1 and PN1(K7E) were subjected to SDS-PAGE on 10% polyacrylamide minigels in preparative wells. After electrophoresis, the gels were transferred to nitrocellulose as described previously (16) . Following blocking in Tris-saline containing 3% BSA (pH 7.4), 0.5-cm strips were cut and transferred to individual wells. The wells were incubated with 125 I-Fheparin at concentrations ranging from 10 to 200 ng/ml in blocking buffer for 3 h at room temperature. At the end of the incubation unbound ligand was removed, and the wells were rinsed 4 times with PBS, dried, and exposed to a Bio-Rad GS-250 molecular imager screen for 1 h. The digitized image was scanned and quantified using a standard curve to convert pixel density units to moles of heparin, based on the known specific activity of the 125 I-F-heparin. Nonspecific binding, approximately 24% of total binding, was determined by incubating 3 wells with a 400-fold excess of unlabeled F-heparin.
RESULTS

RAP-GST Inhibits the Catabolism of 125 I-Th-PN1 Complexes in Human Fibroblasts but Does Not Significantly Inhibit the Binding of 125 I-Th-PN1 Complexes to the Cell Surface-The catabolism of
125 I-Th-PN1 complexes is a multi-step process that starts with cell surface binding and ends with lysosomal degradation (18) . The role of the LRP in 125 I-Th-PN1 complex binding, internalization, and degradation was tested by incubating human fibroblasts (HF) with 125 I-Th-PN1 complexes in the presence and absence of RAP-GST, a protein that inhibits the binding of all known ligands to the LRP (19) . In the first experiment, degradation of 125 I-Th-PN1 complexes was quantitated at 37°C. In previous studies, we have shown that the release of 125 I-tyrosine into the cell culture medium is a quantitative measurement of lysosome-mediated 125 I-Th-PN1 complex degradation by HF (18) . The HF were incubated with 10 ng/ml 125 I-Th-PN1 complexes alone or in the presence of 10 to 800 nM RAP-GST fusion protein. After a 3-h incubation at 37°C, the TCA-soluble 125 I-tyrosine, representing degraded 125 I-Th-PN1 complexes, was quantitated by ␥ counting (Fig.  1A) . Degradation products were predominantly mono-iodo-tyrosine as judged by thin layer chromatography (data not shown). Relative to control cultures that received no RAP-GST, there was a RAP-GST dose-dependent decrease in the generation of 125 I-tyrosine, with a maximum 85% inhibition occurring at the 800 nM dose of RAP-GST. A near maximum level of inhibition of 125 I-Th-PN1 complex catabolism was observed at the relatively low 150 nM concentration of RAP-GST.
Since the initial event in complex catabolism is binding to a high affinity cell surface receptor on HF cells (3), we also evaluated the effect of RAP-GST on the total amount of 125 ITh-PN1 complexes that were cell-associated (cell surfacebound plus internalized) at 37°C (Fig. 1B) and on the amount of complexes that were cell surface-bound at 4°C (Fig. 1C) . HF cells were incubated with 125 I-Th-PN1 complexes for 3 h, in the presence or absence of RAP-GST over the same concentration range used in panel A. The cells were washed to remove unbound complexes and assayed for total cell-associated complexes at 37°C, or cell surface-bound 125 I-Th-PN1 complexes at 4°C, respectively. Surprisingly, at 37°C, RAP-GST caused only a slight reduction in total cell-associated complexes at the highest concentration of 800 nM (Fig. 1B) , although degradation of the 125 I-Th-PN1 complexes was inhibited by 85% at this concentration of RAP-GST (Fig. 1A) . At 4°C RAP-GST did not inhibit complex binding at all, and in fact, slightly increased it. These data demonstrate that nearly all of the binding of 125 ITh-PN1 complexes to the cell surface is to a component other than the LRP. This is in good agreement with our recently published observation that the LRP is required only for the internalization of Th-PN1 complexes and that there is a specific binding site in PN1 that mediates this process (4) .
Soluble Heparin Is a Potent Inhibitor of Th-PN1 Complex Binding and Facilitates the Dissociation of Bound Complexes-
Unlike other heparin-activated SERPINs, the affinity of PN1 for heparin is the same whether the PN1 is free or is in complex with a protease. This was demonstrated by showing that Th-PN1 complexes and free PN1 bound to heparin-Sepharose both eluted at 0.6 M NaCl (20) . Since the binding of 125 I-Th-PN1 complexes to the cell surface was found to be LRP-independent, we next tested the possibility that heparin played a significant role in the initial cell surface binding of 125 I-Th-PN1 complexes to HF and normal MEF. These initial experiments were performed using soluble heparin. In the absence of endocytosis at 4°C, soluble heparin was a potent inhibitor of complex binding to the surface of both cell types (Fig. 2 ). This inhibition due to heparin was in marked contrast to the results of the parallel experiment performed using the LRP antagonis t, RAP-GST (Fig.  1C) . Although RAP-GST inhibits the binding of all ligands, so far identified, to the LRP, it did not affect the cell surface binding of Th-PN1 complexes, whereas soluble heparin competed very effectively for the cell surface binding of Th-PN1 complexes.
The effect of soluble heparin on the dissociation over time of cell surface-bound 125 I-Th-PN1 complexes was also examined (Fig. 3) . 125 I-Th-PN1 complexes were bound to HF and MEF cells at 4°C for 3 h. At the end of the incubation, the cultures were placed on ice and washed four times with PBS to remove unbound ligand. One ml of binding medium was added to the dishes in the presence or absence of 50 nM heparin, and the loss of the 125 I-Th-PN1 complexes from the cells was measured over time. In the absence of soluble heparin, the dissociation rate of 125 I-Th-PN1 complexes was very slow (Fig. 3) . Less than 10% of the complexes dissociated during the 10-min time course without soluble heparin. In sharp contrast, dissociation was very rapid in the presence of 50 nM soluble heparin. Over 80% of the cell surface bound complexes dissociated within 5 min. The slow dissociation from the cell surface in the absence of soluble heparin is very characteristic of ligands bound to cell surface heparins. This is believed to be due to "avidity" because of the high number of binding sites present per heparin chain. The ability of soluble heparin to facilitate dissociation is further evidence that 125 I-Th-PN1 complexes are bound to cell surface heparins at 4°C.
These data suggest that the complexes may indeed bind to cell surface heparins prior to internalization by the LRP. These data do not, however, rule out the possibility that soluble heparin may bind to the complexes and mask a binding site necessary for binding to another component. Nor do they rule out the possibility that the soluble heparin may bind to a component on the cell surface and mask a site to which the complexes would ordinarily bind. These possibilities were further analyzed below using a genetic variant of PN1 that formed complexes with thrombin but was unable to bind heparin.
A Variant Form of PN1 That Is Heparin Activation-deficient Is Unable to Bind to Heparin but Forms SDS-stable Complexes
with Thrombin-We generated a variant form of PN1 in which seven of the basic amino acid residues in the heparin binding region were changed to glutamic acid, PN1(K7E). This form of PN1 has been previously generated using a baculovirus expression system (14) . It displayed a second order rate constant for thrombin inhibition in the absence of heparin identical to native PN1, yet was not activated by heparin (14) . However, previously no direct studies on the heparin binding properties of this variant were done. In the present studies, PN1(K7E) was also expressed using a baculovirus expression system and purified on Cibacron blue-Sepharose as described previously (14) . The inability of PN1(K7E) to bind heparin is shown in Fig.   4A . Two g of PN1 and PN1(K7E) were electrophoresed in a preparative mini-gel and transferred to nitrocellulose as described previously (17) . Strips were cut and blocked in Trissaline BSA and incubated with the indicated concentrations of 125 I-F-heparin. Following washing, the strips were exposed to a Bio-Rad GS-250 molecular imager screen, and the radioactivity in the bands corresponding to PN1 were quantified. The data clearly show a dose-dependent increase in the binding of heparin to native PN1, and a complete absence of binding of heparin to the PN1(K7E) mutant. Although these are the expected data, based on the inability of the PN1(K7E) to be activated by heparin, it was important to establish the degree of loss of heparin binding in the present studies.
To evaluate the subsequent studies performed with the PN1(K7E) variant, we needed to show that the complexes formed between native PN1 and thrombin, and the PN1(K7E) variant and thrombin, had similar properties. Five hundred ng of 125 I-Th were incubated with amounts of active site-titrated PN1 and PN1(K7E) required to achieve complete inhibition of the thrombin. After a 40-min incubation at 37°C, the samples were resolved by SDS-PAGE on 10% polyacrylamide gels. Shown in Fig. 4B is a digitized imaged obtained on a GS-250 molecular imager after a 30-min exposure to the screen. In each lane where complexes were formed, only a trace of free 125 Ithrombin was visible, and the amount of labeled complexes formed using the different forms of PN1 were nearly identical. When the gels were stained for protein, greater than 90% of the PN1 or PN1(K7E) was found to be in the complexes, ruling out a significant role for any uncomplexed PN1 in later experiments. The slightly smaller masses of the complexes formed with the recombinant native PN1 and PN1(K7E) variant are due to the differential mass of the SERPIN moiety of the complex. This is characteristic of SERPINs produced in insect cells using baculovirus expression systems (11, 15, 21) . It is most likely due to carbohydrate compositional differences at consensus glycosylation sites and does not affect protein function in the case of PN1 (4) or the closely related SERPIN, ATIII (11, 15, 21) . Using the PN1(K7E) variant, which was capable of forming complexes with thrombin but unable to bind to heparin, we went on to analyze the role of cell surface bound heparins in the binding of PN1-Th complexes.
I-Th-PN1(K7E) Complexes Are Catabolized at a Much Slower Rate than
125 I-Th-PN1 Complexes-To evaluate the role of the heparin binding site of PN1 in the catabolism of Th-PN1 complexes, 125 I-thrombin was used to make complexes with both native PN1 and the PN1(K7E) variant. The complexes were purified by gel filtration in binding medium and adjusted to equal concentrations (data not shown). Both types of complexes were incubated with normal MEF and MEF-deficient in the LRP (PEA-13 cells), over a 6-h time course at 37°C. At the indicated times, degradation was measured by the appearance of TCA-soluble radioactivity (Fig. 5) . Throughout the time course, there was a consistent 5-fold difference in the rate of degradation of 125 I-Th-PN1 complexes compared with the degradation of 125 I-Th-PN1(K7E) complexes by MEF cells. The much slower rate of degradation of 125 I-Th-PN1(K7E) complexes strongly suggests an important role for the heparin binding site of PN1 in Th-PN1 complex catabolism. In addition, the degradation rate of both 125 I-Th-PN1 and 125 I-Th-PN1(K7E) was greatly reduced in PEA-13 cells that are LRP deficient, demonstrating the important role of the LRP in complex catabolism. Collectively, these data strongly suggest that cell surface heparins and the LRP act synergistically to facilitate the uptake and degradation of Th-PN1 complexes.
To rule out the possibility that both Th-PN1 and Th-PN1(K7E) complexes are taken up at the same rate, but are differentially I-Th-PN1 complexes at a concentration of 100 ng/ml. At the end of a 3-h incubation, the wells were placed on ice and free complexes were removed by aspiration. After 4 washes in binding medium, 1 ml of binding medium alone (Ⅺ, ‚) or binding medium containing soluble heparin at a concentration of 50 nM (f, OE) was added to each well. At the indicated times, the binding medium was removed, and 1 ml of 10% SDS was added to each well to solubilize the cell monolayers. The radioactivity in the cell lysates was quantified by ␥ counting. Error bars indicate 1 standard deviation from the mean of triplicate samples.
compartmentalized, total cell-associated ligand was measured over a 6-h incubation period at 37°C (Fig. 6) . As expected, the total cellular associated radioactivity of MEF incubated with 125 I-Th-PN1(K7E) complexes was much less than that of MEF incubated with 125 I-Th-PN1, ruling out the possibility that 125 I-Th-PN1(K7E) was taken up at an equal rate but was differentially distributed in an intracellular sorting pathway and unable to reach lysosomes efficiently.
Because the data shown in Fig. 5 compares the degradation rate of Th-PN1 complexes prepared using native PN1 purified from HF cells to complexes made using the PN1(K7E) mutant expressed in insect cells, the control experiment shown in Table  I was performed. In this experiment, the degradation rate of 125 I-Th-PN1 complexes formed by reacting 125 I-Th with native PN1 purified from human fibroblasts was compared with that of 125 I-Th-PN1 complexes formed by reacting 125 I-Th with recombinant native human PN1 expressed in insect cells. This experiment was done to rule out the possibility that PN1 pro-
FIG. 4. The variant form of PN1, PN1(K7E), does not bind soluble
125 I-F-heparin but is able to form SDS-resistant complexes with 125 I-thrombin. A, the PN1(K7E) variant was expressed in baculovirus and purified using Cibacron blue-Sepharose (see "Experimental Procedures"). Two g each of PN1 (E) and PN1(K7E) (q) were subjected to SDS-PAGE on 10% gels in preparative wells. At the completion of electrophoresis, the gels were transferred to nitrocellulose, and blocked in Tris-saline BSA. Individual 0.5-cm strips were cut and incubated for 2 h at 22°C with the indicated concentrations of 125 I-F-heparin in blocking buffer. Unbound heparin was removed, and the strips were washed 4 times in blocking buffer, dried, and exposed to a GS-250 molecular imager screen. After 1 h, the screen was scanned and a digitized image was prepared. The radioactivity in the bands was quantified by integrated peak analysis and converted to fmol using a standard curve and the known specific activity of the 125 I-F-heparin. Nonspecific binding of F-heparin was determined as described under "Experimental Procedures" and has been subtracted from the graph shown. B, 500 ng of 125 I-thrombin was incubated with amounts of active site titrated PN1 and PN1(K7E) necessary to achieve complete inactivation in a final reaction volume of 400 l. At the end of a 40-min incubation at 37°C, 5-l aliquots of the reaction mixtures were removed and mixed with an equal amount of 2 ϫ SDS sample buffer and heated to 100°C for 2 min. The samples were subjected to SDS-PAGE on 10% polyacrylamide mini-gels, dried, and exposed to a phospho-imager screen for 30 min. 
FIG. 5.
125 I-Th-PN1(K7E) is catabolized at a much slower rate than 125 I-Th-PN1. 125 I-Th-PN1(K7E) complexes and 125 I-Th-PN1 complexes were formed as described under "Experimental Procedures." Complexes of both types were adjusted to a final concentration of 60 ng/ml in binding medium and incubated with normal mouse embryo fibroblasts and LRP-deficient mouse embryo fibroblasts (PEA-13) for 6 h at 37°C. At the indicated times, aliquots were removed and precipitated in 10% TCA to monitor increases in TCA-soluble radioactivity. 
FIG. 6.
125 I-Th-PN1(K7E) complexes do not accumulate intracellularly.
125 I-Th-PN1(K7E) complexes (q) and 125 I-Th-PN1 complexes (E), both at 100 ng/ml in binding medium, were incubated with normal mouse embryo fibroblasts at 37°C over a 6-h time course. At the indicated times, the cell monolayers were processed as described in the legend to Fig. 2 , and quantified by ␥ counting. Error bars indicate 1 standard deviation from the mean of triplicate samples. duced in insect cells was functionally different than PN1 produced by human cells. The data in Table I clearly show that native PN1 produced by human and insect cells formed complexes with thrombin that were degraded at the same rate by both HF cells and normal MEF cells. There was, interestingly, a consistently higher degradation rate of both types of complexes by the MEF cells, that was independent of the source of PN1. However, these data would argue that any differences in the rate of catabolism of the different PN1 forms are not due to a difference in the sources of the PN1 and PN1 variant.
I-Th-PN1(K7E) Complexes Are Deficient in Cell Surface
Binding-The insensitivity of 125 I-Th-PN1 complex binding to the LRP regulatory protein (RAP), the ability of soluble heparin to compete for Th-PN1 complex binding at 4°C and facilitate dissociation, and the slower turnover rate of Th-PN1(K7E) complexes that are heparin binding-deficient are all consistent with a model in which the initial binding of Th-PN1 complexes is mediated by a cell surface heparin. To test the role of the heparin binding site of PN1 in complex binding directly, the cell surface binding of 125 I-Th-PN1 and 125 I-Th-PN1(K7E) complexes were compared on normal MEF as shown in Fig. 7 . Consistent with this model, the binding of 125 I-Th-PN1(K7E) complexes was only a small fraction of the binding observed with 125 I-Th-PN1 complexes. The binding of the Th-PN1(K7E) complexes corresponds to the amount of complexes that are bound at the cell surface to LRP alone. This is only a small fraction of the greatly augmented binding of Th-native PN1 complexes to the numerous cell surface heparin binding sites present in addition to the cell surface LRP. As demonstrated previously in Fig. 2 , the binding of 125 I-Th-PN1 complexes was efficiently competed for by soluble heparin. In Fig. 7 , no competition of the low level binding of the 125 I-Th-PN1(K7E) complexes was seen, even at high concentrations of soluble heparin, again indicating that the binding of this variant PN1 form was to the LRP component alone and independent of cell surface heparins.
In Fig. 7 , we demonstrated that complexes of thrombin with the PN1(K7E) variant, which lacks heparin binding capacity, are unable to bind to the cell surface effectively. The importance of this initial binding interaction of complexes with cell surface heparins is best illustrated by the markedly reduced catabolism of 125 I-Th-PN1(K7E) complexes (Fig. 5) . Thus, in addition to the requirement for internalization via the LRP, the efficient catabolism of these complexes requires a functional ability to bind cell surface heparins.
DISCUSSION
The LRP mediates the internalization of all protease-SERPIN complexes tested (8, (22) (23) (24) (25) , yet there appear to be differences in the mechanisms of cell association and internalization of protease-SERPIN complexes. Murine LB6 cells internalize uPA-PN1 complexes via a mechanism that is dependent on both uPAR and LRP (8) , and internalization of the complexes is accompanied by co-internalization of uPAR (9) . Th-PN1 complexes do not inhibit binding of uPA-PN1 complexes in LB6 clone 19 cells (8) , indicating that Th-PN1 complexes utilize a different mechanism to reach the LRP for subsequent internalization. In addition, the degradation rates of different protease-SERPIN complexes varies dramatically within a given cell type, suggesting that different mechanisms may be responsible for the initial binding and delivery of the complexes to the LRP for internalization (22) . In the present studies, we demonstrated that the initial binding of 125 I-Th-PN1 complexes to cells is LRP-independent and initiated studies to identify the component that mediates this binding.
In attempting to identify this component, we considered the unusual heparin binding property of Th-PN1 complexes, which, unlike other Th-SERPIN complexes, retain the same affinity for heparin as free PN1 (20) . To test the possibility that cell surface heparins might act as the initial binding site for Th-PN1 complexes, competition studies were done using soluble heparin as the competing ligand. The ability of soluble heparin to compete for the binding of Th-PN1 complexes has been previously demonstrated (18) , but it was assumed that this was due to the partitioning of the complexes at high soluble heparin concentrations, such that they were kept in solution and unable to reach the cell surface. In addition, these studies were never done using purified Th-PN1 complexes. The surprisingly low concentrations of soluble heparin required to compete for the binding of complexes demonstrated in the present studies prompted us to consider more seriously the potential role of cell surface heparins in complex binding and I-Th-PN1(K7E) complexes (q) and 125 I-Th-PN1 complexes (E), both at 35 ng/ml in binding medium, for 3 h at 4°C. Incubations were done in the absence and the presence of the indicated concentrations of soluble heparin. At the end of the incubations, the cultures were processed and assayed for cell surface-bound radioactivity as described in legend to Fig. 1 . The averages of duplicate samples did not vary by more than 10% from the individual values.
internalization. However, since the competition for the cell surface binding of complexes by soluble heparin could be explained by mechanisms other than the involvement of the PN1 heparin binding site, a more direct, genetic approach was taken.
A variant form of PN1, PN1(K7E), which is unable to bind to heparin was constructed and expressed using a baculovirus driven expression system. The PN1(K7E) variant and recombinant native PN1 have been previously characterized (14) . The recombinant native PN1 is biochemically indistinguishable from PN1 purified from human fibroblasts. PN1(K7E) displays a normal second order rate constant for thrombin inhibition, but is not heparin activated. Since direct binding studies of heparin to PN1(K7E) had not been done previously, we measured this variant's capacity to bind heparin after SDS-PAGE and transfer to nitrocellulose. As expected, PN1(K7E) had lost greater than 90% of its heparin binding ability, when compared with native PN1. When the turnover rate of Th-PN1 and Th-PN1(K7E) complexes were tested in parallel, Th-PN1 complexes were degraded at 5 times the rate of Th-PN1(K7E) complexes over a 6-h time period. Binding studies done at 4°C demonstrated that 125 I-Th-PN1(K7E) complexes bound to the cell surface at only a small fraction of the efficiency of 125 I-Th-PN1 complexes.
Taken together, these data strongly support a model in which the initial binding of Th-PN1 complexes to cells is mediated by cell surface heparins. The bound complexes are then subsequently internalized by an LRP-dependent mechanism. The present data suggest that only cell surface heparins are involved in this transfer to the LRP. We cannot rule out the possibility, however, that the heparin binding site in PN1 does not interact with other macromolecules. If that were the case, then removal of this site in the PN1(K7E) variant would mask the involvement of other components. Whether the complexes are transferred to the LRP, or whether the LRP-heparin-Th-PN1 is internalized as a quaternary complex is also unknown. It is interesting to note that normal MEF were able to internalize and degrade small amounts of Th-PN1(K7E), most likely through the action of LRP alone (Fig. 5) . In contrast, LRPdeficient cells (PEA-13) were not able to internalize and degrade Th-PN1(K7E) above levels comparable with fluid-phase pinocytosis alone. In addition, the turnover of native Th-PN1 complexes still occurred to a small extent in the PEA-13 cells, most likely due to the internalization of cell surface heparins. The simplest interpretation of the data is that cell surface heparins act as a mechanism to concentrate Th-PN1 complexes near the cell surface, thus increasing the probability that they will come into contact with the LRP that is constitutively internalized in the presence and absence of bound ligand (26) .
There is evidence that a similar initial heparin binding mechanism may also be used by two other LRP ligands: lipoprotein lipase (27, 28) and thrombospondin-1 (29) . Interestingly, the LRP binding site in PN1 identified in a recent study is proximal to, but distinct from, the heparin binding site of PN1 (4), whereas the LRP binding site in lipoprotein lipase appears to overlap with its heparin binding site and relies on positively charged residues (30) . The distinct biochemical differences in these sites is probably not surprising. While the binding of PN1 to the LRP is dependent on the exposure of the LRP binding site as the result of complex formation with a protease, lipoprotein lipase is LRP binding-competent in the absence of such a mechanism. In addition, given the large number of ligands that bind to the LRP at independent sites, the binding sites in these ligands may well be expected to be very diverse.
In all likelihood, PN1 probably never gets far away from the cell surface after it is synthesized and secreted in vivo. In the model we propose, it remains bound to the cell surface heparins which keep it in an activated state so that it is readily available to react with any target proteases released into the tissues. After complex formation with a target protease, it remains bound to the cell surface heparins but is now competent to bind to the LRP. The control point in the pathway is the exposure of the LRP binding site in thrombin-PN1 complexes that is not present in free PN1. We have recently identified this site (4) and are in the process of characterizing the effects of mutations in this site on PN1 catabolism.
Finally, it should be noted that the use of the term heparin sulfate proteoglycans has been intentionally avoided. It is tempting to speculate that the heparin chains involved in Th-PN1 complex catabolism are classic transmembrane proteoglycans. However, given the recent observation that there are other non-classic proteoglycans, such as those found in specific combinations of ␣ and ␤ integrins which have heparin chains covalently linked to them (31) , it would be premature to identify the biochemical nature of the heparins involved in Th-PN1 complex binding to the cell surface as heparin sulfate proteoglycans.
